Tonato M, Roila F, del Favero A, Tognoni G, Franzosi M G, Pampallona S
Eur J Cancer Clin Oncol. 1985 Jul;21(7):807-10. doi: 10.1016/0277-5379(85)90219-6.
A dose-finding multicenter study was undertaken to evaluate the antiemetic efficacy of domperidone, an antidopaminergic drug, which has been proposed as a suitable alternative to high-dose metoclopramide in the control of cisplatin-induced nausea and vomiting. Forty-five patients were treated with different increasing high doses of domperidone (30, 60, 120 or 150 mg) administered by i.v. infusion over 20 min every 2 hr for a total of four doses for each patient, starting 30 min before chemotherapy. The number of episodes of emesis, the duration of nausea and vomiting and side-effects were recorded. Results do not suggest any specific difference in protective effect between the regimens tested. Moreover, occurrence of serious side-effects indicated that the safety of high-dose domperidone is doubtful.
开展了一项剂量探索性多中心研究，以评估多潘立酮（一种抗多巴胺能药物）的止吐疗效，该药物已被提议作为高剂量甲氧氯普胺在控制顺铂引起的恶心和呕吐方面的合适替代药物。45名患者接受了不同递增高剂量的多潘立酮（30、60、120或150毫克）治疗，通过静脉输注，每2小时一次，每次20分钟，每位患者共接受四剂，在化疗前30分钟开始给药。记录呕吐发作次数、恶心和呕吐持续时间以及副作用。结果并未表明所测试方案在保护作用方面存在任何特定差异。此外，严重副作用的发生表明高剂量多潘立酮的安全性存疑。
